Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis.
Lucijanic M, Krecak I, Soric E, Sabljic A, Galusic D, Holik H, Perisa V, Moric Peric M, Zekanovic I, Kusec R. Lucijanic M, et al. Among authors: galusic d. Leuk Res. 2022 Aug;119:106905. doi: 10.1016/j.leukres.2022.106905. Epub 2022 Jun 21. Leuk Res. 2022. PMID: 35759912 No abstract available.
Ruxolitinib treatment improves muscle mass in patients with myelofibrosis.
Lucijanic M, Galusic D, Soric E, Sedinic M, Cubela M, Huzjan Korunic R, Pejsa V, Kusec R. Lucijanic M, et al. Among authors: galusic d. Ann Hematol. 2021 Apr;100(4):1105-1106. doi: 10.1007/s00277-020-04243-8. Epub 2020 Sep 1. Ann Hematol. 2021. PMID: 32870367 No abstract available.
Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases.
Galusic D, Basic-Kinda S, Pijuk A, Milunovic V, Dreta B, Franjic N, Coha B, Sincic-Petricevic J, Gacina P, Pejsa V, Lucijanic M, Aurer I. Galusic D, et al. Hemasphere. 2022 Nov 15;6(12):e807. doi: 10.1097/HS9.0000000000000807. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36407092 Free PMC article.
23 results